Project Grant R01AR086237
- This $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify differences in DNA regulatory elements that control gene expression in skin cells from individuals of different ancestral backgrounds. The research team at the Icahn School of Medicine at Mount Sinai will utilize advanced genomic techniques, including...
- The federal Project Grant award of $649,391 provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting research to enhance healing after injury. The overarching objective is to define the mechanisms that restrain tissue regeneration in order to develop new therapeutics to improve healing of the gut and skin following injury or infection. The 5-year project, which...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to define the contributions of metabolic regulation of macrophages to skin wound healing. The central hypothesis is that glutamine metabolism controls the inflammatory niche during tissue repair in the skin, with macrophages as the primary mediators. The $489,533 award, effective...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $465,291 to the Massachusetts Institute of Technology (MIT) to conduct research on the determinants of colonization for commensal skin bacteria. The research aims to define the rules governing on-person bacterial evolution, ecology, and colonization, with the long-term goal of informing the...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $404,140 to Cedars-Sinai Medical Center to investigate the role of the NLRP10 protein in regulating wound healing in cutaneous leishmaniasis. The research aims to identify the mechanisms by which NLRP10 mitigates fibroblast senescence and aids the wound repair response in the presence of...
- This federal Project Grant award of $528,558.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The goal of the research project is to study the immune system mechanisms underlying treatment resistance and paradoxical inflammatory side effects in patients with atopic dermatitis who receive the antibody therapy dupilumab. The research will...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- This $224,100 federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify epigenetic factors that control the longevity of epidermal stem cells in adult skin. The project aims to elucidate the functional role of epigenetic regulators and their corresponding histone modifications in maintaining the longevity of hair...
- The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant of $413,655 on August 1, 2025 to Arizona State University (ASU) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research to develop biomaterials with temporal control of proteins, such as Bone Morphogenetic Proteins (BMPs), to enhance bone repair. The research aims to mimic natural extracellular matrix interactions and synergies...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,070,827 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Icahn School of Medicine at Mount Sinai. This grant aims to identify novel microbial factors that can enhance wound repair, a significant public health issue with over 100 million new acute skin wounds annually and substantial treatment costs exceeding $25 billion. The research will leverage cutting-edge spatial omics technologies and bacterial genetics to investigate how specific Staphylococcal toxins can modulate epidermal and dermal repair processes, with the goal of uncovering new pathogen-associated molecular patterns that could serve as pro-repair signals. The award has a project period from September 1, 2025 to August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.1m | 8/25/25 |